ArticlePharmacogenomics
Pharmacogenomics education among professional societies: assessing practices and future needs.
Article in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacogenomics of Antineoplastic Therapy in Children: Genetic Determinants of Toxicity and Efficacy.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo study the availability, perceived necessity, barriers, and preferred formats for pharmacogenomics (PGx) education disseminated to healthcare professionals by professional societies. MATERIALS &
methodsA web-based survey of professional organizations affiliated with the Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG), a U.S.-based initiative coordinated by the National Human Genome Research Institute, targeted representatives who could reflect their organization's educational stance.
resultsOf the 34 unique responses analyzed, most organizations provided general and genomic education (94.1% and 82.4%, respectively), and 70.6% offered PGx-specific education. Most (61.8%) indicated they either needed major additions to the education they provide or had no PGx education resources. Key barriers included a lack of PGx focus within organizations (78.1%) and challenges in maintaining an up-to-date curriculum (75.0%). Preferred educational formats were live webinars (84.4%), hybrid courses (78.1%), and self-study modules (78.1%).
conclusionsOur study identifies gaps in PGx education across professional organizations and underscores the need for resources to advance clinician competence in PGx. While some PGx education is available, many organizations require additional resources and support. Enhancing PGx education through targeted initiatives by organizations like ISCC-PEG may improve clinician competence and the integration of PGx into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.